Despite rather extensive familiarity with biological effect of anti-HER2/neu and anti-EGFR on the vitality of cancer cell populations and it’s application in clinical oncology, there has correspondingly been surprisingly little research devoted to the molecular design, chemical synthesis and potency evaluation of covalent anthracycline and especially gemcitabine immunochemotherapeutics[97]. This evidence concerns the gene EGFR and cancer.